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ORIGINAL ARTICLE
Cross-Sectional Versus Sequential Quality Indicators of Risk
Factor Management in Patients with Type 2 Diabetes
Jaco Voorham, MSc,*†‡ Petra Denig, PhD,*‡ Bruce H. R. Wolffenbuttel, MD, PhD,§
and Flora M. Haaijer-Ruskamp, PhD*‡
Background: The fairness of quality assessment methods is under
debate. Quality indicators incorporating the longitudinal nature of
care have been advocated but their usefulness in comparison to more
commonly used cross-sectional measures is not clear.
Aims: To compare cross-sectional and sequential quality indicators
for risk factor management in patients with type 2 diabetes.
Methods: The study population consisted of 1912 patients who
received diabetes care from one of 40 general practitioners in The
Netherlands. Clinical outcomes, prescriptions, and demographic
data were collected from electronic medical records. Quality was
assessed for glycemic, blood pressure, and lipid control using
indicators focusing on clinical outcomes, and treatment in relation to
outcomes. Indicator results were compared with a reference method
based on national guidelines for general practice.
Results: According to the reference method, 76% of the patients
received management as recommended for glycemic control, 58%
for blood pressure control, and 67% for lipid control. Cross-sec-
tional indicators looking at patients adequately controlled gave
estimates that were 10–25% lower than the reference method.
Estimates from indicators focusing on uncontrolled patients receiv-
ing treatment were 10–40% higher than the reference method for
blood pressure and glycemic control. Sequential indicators focusing
on improvement in clinical outcomes or assessing treatment modi-
fications in response to poor control gave results closer to the
reference method.
Conclusions: Sequential indicators are valuable for estimating qual-
ity of risk factor management in patients with diabetes. Such
indicators may provide a more accurate and fair judgment than
currently used cross-sectional indicators.
Key Words: quality indicators health care, diabetes mellitus,
quality of health care, outcome and process assessment (health
care)
(Med Care 2008;46: 133–141)
Quality of diabetes care has received a lot of attention overthe past decade, and room for improvement of glycemic,
blood pressure, and lipid management has repeatedly been
shown.1–6 There is, however, debate about the fairness of indi-
cators used to assess quality of care, especially for external
accountability.7–10 Many studies looking at quality of care use a
cross-sectional approach where processes and outcomes of care
are measured at one point in time.2–6,11–13 This approach may be
limited, because it does not take the longitudinal nature of
chronic patient care into account. One study showed that, al-
though quality of care may seem to improve over time using
cross-sectional assessments, a longitudinal approach can show
that specific patient groups are not benefiting.9 There are also
discrepancies between indicators based on process and outcome
measures. It has been shown that only looking at outcomes of
care can result in an inaccurate view.14,15 Such indicators do not
differentiate between patients receiving suboptimal care and
patients that are difficult to manage or noncompliant. Therefore,
these indicators are affected by case-mix differences. Indicators
reflecting risk factor management in relation to specific out-
comes have been advocated to overcome this problem.14,16–20
Especially, the ability to recognize the failure to initiate or
intensify treatment when indicated could provide insights im-
portant to target interventions.10,18,19,21,22 Rodondi et al14 have
argued that care provided by a physician should be evaluated
using a decision tree in which actions and events that do imply
appropriate care, despite a target level not being achieved, are
acknowledged.
To better understand the added value of such an ap-
proach, we examined the possible benefits of sequential over
cross-sectional quality indicators of risk factor management
by comparing both to a reference method. This reference
method was based on a detailed assessment of relevant
actions and events at the individual patient level.
METHODS
In a cohort study, the quality of glycemic, blood pres-
sure, and lipid management was assessed for patients with
type 2 diabetes. We evaluated indicators focusing on clinical
outcomes (HbA1c, systolic blood pressure, total cholesterol),
and indicators focusing on treatment related to these out-
comes, using target levels from national guidelines for clin-
ical practice. Percentages of patients with risk factor man-
agement according to these guidelines were determined using
a common cross-sectional indicator and several newly devel-
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oped sequential indicators, and compared with the reference
method. Calculations were made at the aggregated level,
which is common for external quality assessment, and at the
individual patient level, because quality indicators may also
be used for internal purposes to identify patients not receiving
optimal care.23
The study was conducted conforming to the Dutch
guidelines on the use of medical data for scientific research.
For medical record research of anonymous data, no Institu-
tional Review Board approval is needed.
Study Population and Setting
Our study population consisted of 1912 patients who
received diabetes care from one of 40 general practitioners
(GPs) participating in a regional project in 2004 and 2005.24
All patients with a diagnosis of type 2 diabetes at the
beginning of 2004 were included. Among participating GPs,
20% practiced in a rural area, 18% worked in a solo practice,
and 16% were dispensing.
In our study area, a regional diabetes facility offers
support to GPs; primary care patients with type 2 diabetes can
be referred to the diabetes facility. This outpatient facility
conducts simple physical examinations and laboratory tests of
blood and urine during 3-monthly and yearly diabetes fol-
low-up visits on behalf of the GPs. They report results back
to the GP, who remains responsible for further treatment of
the patient. All GPs prescribe electronically, and all clinical
information is stored in electronic patient records at the GP
practices and an electronic diabetes registry at the diabetes
facility.
For the drugs included, there was no copayment be-
cause they were all priced below the maximum reimburse-
ment limits set by the Dutch government for both public and
private health insurance funds. All drugs can be prescribed by
GPs according to the guideline recommendations.
Data Collection and Quality Indicators
Clinical outcomes, prescriptions, coronary comorbidity
(angina pectoris, myocardial infarction, heart failure, coro-
nary artery bypass graft, coronary angioplasty, atrium fibril-
lation), other diabetes-related conditions (stroke, transient
ischemic attack, peripheral arterial disease, neuropathy, am-
putations, retinopathy), and demographic data were collected
for the period January 2003 until June 2005. Prescriptions
collected include all GPs’ medication orders. Information
was extracted by automatic data collection from the elec-
tronic patient record systems at the general practice office and
the regional diabetes facility. The data extraction method
relies on text recognition to ensure retrieval of information
from “free text” segments of patient records in addition to
data collection from structured tables. This approach is com-
parable to manual patient record abstraction, and was found
to be 94–100% sensitive to detect the clinical outcomes
relevant for this study, irrespective of registration method or
information system used by the GP.25
TABLE 1. Quality Indicators of Risk Factor Management
Indicators Focusing on Clinical Outcomes
A Patients “controlled”
Numerator Patients with measurement at or below target level in evaluation year
Denominator All patients with measurements
B Uncontrolled patients “achieving control”
Numerator Patients with measurement below the target level in evaluation year
Denominator Patients above target in preceding year
C Uncontrolled patients with “improvement”
Numerator Patients with clinically relevant improvement in measurements between evaluation and
preceding year
Denominator Patients above target level in preceding year
D Patients “controlled or improving”
Numerator Patients with measurement above target level in preceding year and clinically relevant
improvement in evaluation year, or with measurement below target level in both years
Denominator All patients with measurements
Indicators Focusing on Treatment in Relation to Outcomes
E Uncontrolled patients “treated”
Numerator Patients treated in evaluation year
Denominator Patients with measurement above target level in evaluation year
F Patients “uncontrolled then treated”
Numerator Patients treated in evaluation year
Denominator Patients with measurement above target level in preceding year
G Patients with “treatment modified
when indicated”
Numerator Patients started or intensified treatment in evaluation year
Denominator Patients with last measurement above target in preceding year
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We evaluated 4 quality indicators focusing on clinical
outcomes, and 3 indicators focusing on treatment related to
outcomes (Table 1). For both aspects, the most commonly
used cross-sectional indicator was included. The other se-
lected indicators were sequential indicators that incorporate
different levels of the longitudinal aspect of patient care, as
identified in other studies looking at the evaluation of appro-
priate care.14,15,21,26 Table 1 describes for each indicator the
patients included in the numerator and denominator.
The last measurement of a risk factor in a year was used
for all indicators. Patients were included with at least 1 risk
factor measurement in 2003 and in 2004 to allow for sequen-
tial assessments. We excluded patients without risk factor
measurements from both the tested indicators and the refer-
ence method, because in both cases they would fall in the
same category of inadequate care.
Based on the national guidelines for general practice at
the time of the study, the following target levels were used to
identify controlled risk factors: HbA1c7.0%, systolic blood
pressure 140 mm Hg, and total cholesterol 5.0 mmol/L.
Changes in risk factor level considered clinically relevant
were set at 0.3% for HbA1c, 5 mm Hg for systolic blood
pressure, and 0.5 mmol/L for total cholesterol.
The cross-sectional indicator on clinical outcomes is
the most widely used measure of patients “controlled” (indi-
cator A) (eg, in the United States, United Kingdom, and The
Netherlands).27–30 This indicator looks at patients below
target level as a proportion of all patients. The sequential
indicators B and C focus on patients that were previously
insufficiently controlled.9,21 Indicator B identifies patients
“achieving control,” that is, patients moving from being
uncontrolled in the preceding year to controlled in the current
year. Indicator C acknowledges patients with any clinically
relevant “improvement” in risk factor level. Indicator D is a
combined measure identifying patients “controlled or im-
proving” as a proportion of all patients.
The indicators looking at treatment in relation to out-
comes focus on patients who are in need of treatment, that is,
insufficiently controlled patients. The cross-sectional indica-
tor identifies all of such patients concurrently “treated” (in-
dicator E). This is a generic approach for assessing guideline
compliance to the recommendation that patients with diabetes
with uncontrolled risk factors should receive treatment.1,31
This indicator has been proposed by the Dutch Institute for
Healthcare in their recent set of quality indicators for diabetes
management.32 Both sequential indicators (F and G) look at
treatment in reaction to elevated risk factor levels, thus
incorporating the time sequence of observation and action in
contrast to the cross-sectional indicator. Patients who receive
treatment after being uncontrolled in the preceding period are
identified with the “uncontrolled then treated” indicator F.
Finally, indicator G also acknowledges cases of “treatment
intensified when indicated” by identifying all uncontrolled
patients not on maximal medication for whom treatment is
either initiated or intensified.
Treatment Definitions
Treatment modifications were determined by com-
paring changes in prescriptions during the evaluation year
with treatment observed in the final 6 months of the
preceding year. A treatment modification was considered
intensification when a new drug class was started or added
or the dosage of medication was increased. A switch to
insulin was considered intensification, but switches to
other drug classes without continuation of the original
medication were not considered treatment intensification,
because such switches could be due to side effects. A
prescription was considered discontinued if it was not
repeated within 120 days from the calculated end date.
For glucose-lowering medication, we included 6 drug
classes (insulin, metformin, sulfonylureas, acarbose, thiazo-
lidinediones, and repaglinide), for antihypertensive medica-
tion 5 classes (centrally acting antihypertensives, diuretics,
beta-blockers, calcium-channel blockers, and renin-angioten-
sin system inhibitors), and for lipid-lowering medication 5
classes (statins, fibrates, bile acid sequestrants, nicotinic acid
derivatives, and ezetimibe).
The definitions for maximal medication were derived
from treatment recommendations for general practitioners.
For glucose-lowering medication, prescription of insulin
was defined as having reached maximal medication. For
blood pressure lowering medication, 3 or more drug
classes prescribed at maximum maintenance dosage was
considered as maximal medication. For lipid-lowering
medication, prescribing the maximum dosage of a drug
was considered maximal medication. Combination of lipid-
lowering drugs is not recommended in general practice. Dosage
recommendations were obtained from the Dutch Pharmacother-
apy Compendium.33
Reference Method
The reference method involved a stepwise review of
care as documented in the electronic patient records. Events
and actions were assessed at the individual patient level,
using all information on changes in prescriptions and relevant
clinical outcomes using an automated procedure (Fig. 1). This
method acknowledges to some extent that care can be appro-
priate in patients not reaching strict target levels, by focusing
on the recommended management in relation to outcomes, as
has been advocated before.14,16–20 It builds upon the work
described by Rodondi et al,14 extended with a follow-up
observation to accept management as being in line with
guideline recommendations when patients achieved target
levels during a monitoring period or medication was modified
after a follow-up measurement of the risk factor.
Management was assessed for each of the risk factors
separately. The following situations were considered as man-
agement as recommended in the guidelines:
1. Risk factor was at or below target level, and therefore
adequately controlled,
2. Risk factor was above target level but medication was
started or intensified within 28 days,
3. Risk factor was above target level but maximal medication
according to guideline recommendations for general prac-
tice was already being prescribed,
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4. Risk factor was above target level but target level was
achieved during a monitoring period of not more than 120
days,
5. Risk factor was above target level but medication was
started or intensified after a monitoring period during
which the risk factor was measured again.
Because diabetes consultations should occur 4 times a
year according to the diabetes guidelines, we used a moni-
toring period of 120 days, allowing for some variation in the
period between 2 regular consultations. The data origin and
collection method were equal for the reference method and
the tested indicators, ensuring that differences observed were
due to indicator definitions and not to differences in com-
pleteness of data collection.
Analysis
Percentages of all patients with management as rec-
ommended were calculated per risk factor using the refer-
ence method. Quality assessments according to each of the
indicators A to G were compared with results of the ref-
erence method in the same patient population. The abso-
lute difference as well as percentages of disagreement
between both estimates were calculated. Significance of
differences was assessed by the McNemar statistic for
paired proportions. To test whether the results might be
sensitive to the set target levels or population case-mix, we
repeated the analyses using levels of poorly controlled
patients instead of adequately controlled patients, that is,
HbA1c 8.5%, systolic blood pressure 160 mm Hg, and
FIGURE 1. Decision tree used in the Reference Method for assessing risk factor management; gray boxes indicate patients
who are considered as being not managed according to the guideline recommendations.
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total cholesterol 6.0 mmol/L, and after stratification on
comorbidity (yes/no).
Positive and negative likelihood ratios were calculated
with 95% confidence intervals. These ratios express the
ability of an indicator to predict the quality assessment at the
individual patient level. Likelihood ratios combine sensitivity
and specificity into 1 measure, and are insensitive to the
underlying probability of risk factor management according
to the guidelines. Likelihood ratios between 0.5 and 2 were
considered to reflect poor predictors, whereas ratios below
0.2 or above 5 indicate moderate to strong predictors.
RESULTS
Study Population
Demographic characteristics, degree of control, and
treatment in the study population are presented in Table 2.
Respectively 83%, 88%, and 73% of the 1912 patients had at
least 1 measurement of HbA1c, blood pressure, and total
cholesterol recorded in 2004. Mean risk factor levels were
7.1% for HbA1c, 146.6 mm Hg for systolic blood pressure,
and 4.9 mmol/L for total cholesterol. The average 10-year
absolute risk for coronary heart disease according to the UK
Prospective Diabetes Study risk engine34 was 23.4%. Glu-
cose-lowering medication was prescribed to 83.6%, antihy-
pertensive medication to 71.2%, and lipid-lowering medica-
tion to 46.9% of the patients. Coronary comorbidity and other
diabetes-related conditions were each recorded in 15% of the
patients.
Reference Method
According to the reference method, 75.8% of the pa-
tients received management as recommended for glycemic
control, 58.3% for blood pressure control, and 66.4% for lipid
control. Of patients with the recommended glycemic man-
agement, 71.5% were already on target, treatment was started
or intensified in another 8.8%, 13.8% were on maximal
medication, 2.4% returned on target, and 3.5% received a
change in medication during follow-up. For blood pressure,
54.3% of such patients were already on target, in 7.4%
treatment was started or intensified, 22.9% were already on
maximal medication, 11.1% returned to target, and 4.3%
received a change in medication during follow-up. For lipid
control, 83.6% were on target, treatment was started or
intensified in 10.2%, only 0.1% were on maximal medication,
4.1% returned to target, and 2.0% received a change in
medication during follow-up.
Of patients who were above target, 52.8%, 61.0%, and
75.0% did not receive any action for glycemic, blood pres-
sure, and lipid control respectively. These patients were
considered as being not managed according to the guideline
recommendations.
Comparison at the Aggregated Level
Table 3shows the differences in percentages of patients
assessed as receiving the recommended risk factor manage-
ment according to the indicators in comparison to the refer-
ence method. When looking only at clinical outcomes (indi-
cators A–D), the cross-sectional indicator looking at patients
“controlled” (A) and the indicator focusing on patients
“achieving control” (B) gave lower estimates than the refer-
ence method. For instance, indicator A gave a result for blood
glucose management that was almost 22% lower than the
reference. For indicator B the absolute difference was 32%.
For all 3 risk factors, assessments obtained with sequential
indicators focusing on patients with improved outcomes (C
and D) gave results considerably closer to the reference
method. Indicator C, however, showed higher percentages of
disagreement than indicator D. Comparing the indicators with
identical patient populations (pairs B,C and A,D) showed that
the more complex indicators (C and D) provided results that
were significantly different from the simple indicators and
closer to the reference method for all 3 risk factors.
The cross-sectional indicator focusing on uncontrolled
patients “treated” (E) and the sequential indicator of patients
“uncontrolled then treated” (F) gave estimates 34–48%
higher than the reference method for blood pressure and
glycemic management (Table 4). For these risk factors, the
indicator looking at “treatment modified when indicated” (G)
resulted in better estimates, although still 15% lower than the
reference method. Also, the percentage disagreement was
smallest for this indicator. For lipid control, the indicator of
patients “uncontrolled then treated” (F) produced an assess-
ment equal to the reference method, but the percentage
disagreement was similar to the other indicators. Comparing
the treatment indicators with identical patient populations
(pair F,G) showed significant differences in favor of the more
complicated indicator (G) for glycemic and blood pressure
management.




Age (yr) 66.8 (12.4)
Male gender (%) 45.4
Diabetes duration (yr) 5.7 (5.4)
HbA1c (%) 7.1 (1.1)
Systolic blood pressure (mm Hg) 146.6 (20.0)
Total cholesterol (mmol/L) 4.9 (1.0)
HDL-cholesterol (mmol/L) 1.3 (0.4)
LDL-cholesterol (mmol/L) 2.8 (0.9)
Triglycerides (mmol/L) 2.0 (1.2)
Body mass index (kg/m2) 29.5 (5.4)
UKPDS 10-yr overall cardiovascular risk (%) 23.4 (15.8)
Presence of coronary conditions (%) 15.3
Presence of other DM-related conditions (%) 14.6
Not using glucose lowering medication (%) 17.4
Only using oral glucose lowering medication (%) 65.4
Only using insulin (%) 7.4
Using insulin  oral agents (%) 9.8
Using blood pressure lowering medication (%) 71.2
Using lipid lowering medication (%) 46.9
No. chronic medicines used 3.4 (1.9)
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Sensitivity Analysis
When comparing the assessments using higher target
levels, both cross-sectional indicators (A and E) showed
results that were at least 10% closer to the reference method
for glycemic and blood pressure management. The sequential
indicators of patients with “improvement” (C) and “treatment
modified when indicated” (G) deteriorated in most cases,
implying that for assessing poor risk factor management such
sequential indicators were not superior to cross-sectional
indicators.
The analyses stratified for patients with or without
coronary and/or diabetes-related comorbidity showed almost
identical results for most indicators. As expected, estimates
from indicators A and B were slightly lower in patients with
comorbidity. For the sequential indicators C and G, differ-
ences in percentages between the 2 cohorts were small
(1–6%).
Comparison at the Individual Patient Level
For indicators A and B, positive likelihood ratios could
not be calculated because all patients assessed as being
managed in line with the guideline recommendations fall by
definition into the same category for the reference method.
The indicator of patients with “improvement” (C) showed
positive likelihood ratios between 1.5 and 2, implying it to be
a poor predictor for risk factor management according to the
guidelines (Table 4). The indicator of patients “controlled or
improving” (D) performed significantly better with ratios
between 2 and 3. The negative likelihood ratios were between
0.2 and 0.5 for most of these indicators, signifying weak
predictors for identifying individual patients not receiving
management as recommended in the guidelines. The sequen-
tial indicators did not perform significantly different from the
cross-sectional indicators regarding these values.
For the indicators focusing on treatment, the “treatment
modified when indicated” indicator (G) showed positive like-
lihood ratios between 2 and 5, indicating a weak predictor for
identifying patients receiving risk factor management as rec-
ommended. The other indicators performed significantly
worse, with positive likelihood ratios below 2 except for lipid
control. For predicting risk factor management not in line
with the recommendations at the individual patient level, all
indicators performed equally with negative likelihood ratios
of around 0.5 (Table 4).
DISCUSSION
This study showed that the commonly used quality
indicator focusing on the number of patients controlled may
lead to inaccurate judgments of risk factor management. The
simple sequential indicator looking at patients switching from
above to below target levels also gave low estimates of the
TABLE 3. Overview of the Results of the Indicators A to G, Compared to the Reference Method*




















A Patients “controlled” 21.7† 0 21.7 1359 26.9† 0 26.9 1513 11.1† 0 11.1 1096
B Patients “achieving control” 31.7† 0 31.7 731 29.7† 0 29.7 1102 15.9† 0 15.9 687
C Patients with “improvement” 10.9† 13.8 24.8 731 1.3 18.1 16.9 1102 1.4 16.0 17.5 687
D Patients “controlled or improving” 10.5† 7.4 18.0 1359 4.4† 13.2 17.6 1513 2.1 10.0 12.1 1096
E Uncontrolled patients “treated” 48.0† 49.5 1.5 729 39.9† 44.5 4.4 1150 13.0† 19.2 6.3 624
F Patients “uncontrolled then treated” 34.7† 36.8 2.2 768 33.8† 39.8 5.7 1096 0.7 14.9 14.1 673
G “Treatment modified when indicated” 16.1† 9.5 25.7 768 15.3† 6.3 21.6 1096 19.8† 5.2 25.0 673
*Assessments made for all patients with recorded risk factor measurements.
†Difference between indicator and reference is significant at P  0.05 level.
, Difference between reference and indicator estimates of percentages of patients with the recommended management; % FP, percentage of false positives; % FN, percentage
of false negatives; n, number of patients.
TABLE 4. Likelihood Ratios (with 95% Confidence Intervals) for the Different Indicators
Indicator
Glycemic Management Blood Pressure Management Lipid Management
Negative Positive Negative Positive Negative Positive
A Patients “controlled” 0.28 (0.26–0.31) — 0.47 (0.44–0.49) — 0.16 (0.15–0.18) —
B Patients “achieving control” 0.47 (0.43–0.52) — 0.58 (0.55–0.61) — 0.29 (0.26–0.31) —
C Patients with “improvement” 0.64 (0.54–0.75) 1.49 (1.27–1.76) 0.53 (0.46–0.59) 1.80 (1.59–2.04) 0.49 (0.42–0.58) 1.90 (1.62–2.22)
D Patients “controlled or improving” 0.34 (0.30–0.39) 2.44 (2.13–2.79) 0.44 (0.40–0.49) 2.22 (2.00–2.46) 0.26 (0.22–0.30) 2.55 (2.19–2.97)
E Uncontrolled patients “treated” 0.52 (0.28–1.36) 1.03 (0.46–2.27) 0.42 (0.31–0.56) 1.22 (0.90–1.61) 0.34 (0.28–0.41) 2.93 (2.44–3.51)
F Patients “uncontrolled then treated” 0.63 (0.33–1.22) 1.02 (0.53–1.97) 0.50 (0.38–0.66) 1.16 (0.89–1.51) 0.45 (0.39–0.51) 2.58 (2.24–2.97)
G “Treatment modified when indicated” 0.56 (0.49–0.63) 2.38 (2.11–2.69) 0.51 (0.47–0.56) 4.54 (4.19–4.91) 0.64 (0.59–0.70) 4.58 (4.22–4.97)
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quality of such care, similar to the cross-sectional indicator
that only looks at the current risk factor level. More complex
indicators that focus on uncontrolled patients with clinical
improvements provided quality estimates that corresponded
better with a detailed evaluation of risk factor management.
Furthermore, our results showed the limited value of the
cross-sectional indicator looking at uncontrolled patients
treated. The observation that a patient with an elevated risk
factor level is receiving medication is a poor predictor of
management according to guideline recommendations, and
will result in high estimates of quality. But again, results of
a simple sequential indicator looking at uncontrolled pa-
tients subsequently treated were only slightly different
from this cross-sectional indicator. Focusing on intensifi-
cation of treatment in uncontrolled patients led to clearly
better quality assessments. At the individual patient level,
we observed that the more complex sequential indicators
were superior in identifying patients receiving risk factor
management as recommended. For assessing the quality of
treatment focusing on poorly instead of adequately con-
trolled patients, however, simple cross-sectional indicators
seemed to be equally sufficient.
Ideally, one might want to assess the quality of risk
factor management by looking at detailed clinical and thera-
peutic information for each patient over time. This approach
has resulted in the development of clinically detailed indica-
tors that require individual patient chart review.35–37 This is
time-consuming and difficult to implement when using auto-
mated data for quality assessment. Our reference method
involves detailed individual patient assessment over time but
is not feasible to conduct on a large scale. Therefore, we
evaluated several simpler alternatives on their ability to
correspond with this reference method.
The quality assessments observed in our study using
simple cross-sectional indicators were similar to those found
previously in other studies. The percentages of patients with
adequate blood pressure control (32%), lipid control (56%),
and glycemic control (54%) were within the range of out-
comes reported in recent studies with comparable patient
groups and target levels in the United States,3,6,17,38 Italy,39
and The Netherlands.40,41 Also, percentages of patients
treated (95%, 79%, and 38%) were within ranges observed in
other studies for these risk factors.3,6,38
The clear advantage of sequential indicators is that they
are capable of quantifying alterations in outcomes and pro-
cesses of care in response to outcomes. The indicator of
patients “controlled or improving,” and especially the indi-
cator “treatment modified when indicated” incorporate sev-
eral factors important to quantify adequate risk factor man-
agement, as pointed out by others.14,15,18,21,42 Using these
indicators can be expected to result in a reduction of the
negative incentives to avoid patients that are more difficult to
control. Our study demonstrated that such indicators can be
applied in practice using routinely recorded information on
treatment and outcomes, and are valuable for estimating
quality of diabetes management at the aggregated level.
For our primary analyses we used target levels as
indicated by the national guidelines for general practice.
However, the use of strict target levels for the entire patient
population is under debate.43 We tested the indicators also
with high target levels. The proportion of patients that would
not benefit from achieving those targets is smaller, and
patient case-mix is therefore less important than when focus-
ing on aggressive management. We found that the advantage
of sequential indicators was larger when using strict target
levels. This could imply that sequential indicators may coun-
teract some of the case-mix problems observed in commonly
used indicators focusing on strict target levels.
The assessed indicators performed comparably for gly-
cemic and blood pressure control, but for lipid control the
differences between the indicators were less pronounced.
This could be due to physicians reacting less to elevated
cholesterol levels than to elevated HbA1c and blood pressure
levels. Although the national guidelines at the time of our
study recommended that lipid lowering treatment should be
guided by cholesterol levels, there were already recommen-
dations that all patients with diabetes are eligible for such
treatment.44
Limitations
Both the reference method and the indicators were
tested in a population that included patients that may not
benefit from (aggressive) treatment. This implies that justifi-
able decisions not to manage risk factors are not captured as
being in line with guideline recommendations. We did not
have information on contraindications or circumstances, such
as patients’ limited life expectancy or treatment refusal, or
competing demands, which could justify nonintervention.
There may be other conditions that warrant more immediate
attention at a particular visit than risk factor management.
Although our reference method allows for an extended period
of 120 days in which actions can be taken, some patients may
still be incorrectly classified as being in need of additional
treatment. This problem is not specific for our study but
affects quality assessments in general. When sufficient infor-
mation is available, it can be solved by excluding these
patients from the indicators. For our study, we expect that
comparisons between the indicators and the reference method
maintain their validity, because this lack of information will
affect the tested indicators similarly. The stratified analysis
confirmed that our comparative findings were robust for
variations in patient population regarding comorbidity.
Furthermore, our data did not allow assessing actions
taken regarding lifestyle, treatment compliance, insulin regi-
men intensifications, or referrals to a medical specialist.
Therefore, we considered patients that were uncontrolled but
on maximal medication—as defined in this study—as receiv-
ing management as recommended. In some cases, however,
further actions might have been warranted and possible.
The feasibility of using sequential indicators is ex-
pected to be good. The data required for their calculation
include risk factor measurements and medication treatment
information in 2 concurrent years, which are usually regis-
tered during regular care.
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Implications for Quality Assessment
Quality indicators can be used for internal quality
improvement and for external purposes. For internal use, it is
helpful to identify patients who possibly receive suboptimal
management. Our study showed that for this purpose the
simple, commonly used indicators performed as well as the
more complex indicators. In other words, to optimize patient
care at the individual level sequential indicators do not
provide a clear benefit.
For external use, such as public accountability, indica-
tors need to provide a fair view of the risk factor manage-
ment. Indicators looking only at patients below strict target
levels may underestimate the quality of care. Substitution of
such indicators with the sequential “controlled or improving”
indicator, which considers both patients that maintain control
and those that achieve clinically relevant improvements, can
provide a more meaningful assessment of risk factor man-
agement.
Indicators focusing on the percentage of uncontrolled
patients receiving medication overestimate treatment quality,
because they do not take any recommendations for treatment
intensification into account. For assessing treatment quality
we recommend the use of a sequential indicator measuring
the modification of treatment when indicated. The advantage
of including also the “controlled or improving” indicator is
that this considers all patients, and not just the ones who are
uncontrolled as is done in the treatment oriented indicators.
As has been stated before, good quality of risk factor man-
agement incorporates achieving control in uncontrolled pa-
tients as well as maintaining control in those controlled.9,14
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